CU20130159A7 - Derivados de la piperidina 3- espirocíclica como agonistas de receptores de la ghrelina - Google Patents

Derivados de la piperidina 3- espirocíclica como agonistas de receptores de la ghrelina

Info

Publication number
CU20130159A7
CU20130159A7 CU2013000159A CU20130159A CU20130159A7 CU 20130159 A7 CU20130159 A7 CU 20130159A7 CU 2013000159 A CU2013000159 A CU 2013000159A CU 20130159 A CU20130159 A CU 20130159A CU 20130159 A7 CU20130159 A7 CU 20130159A7
Authority
CU
Cuba
Prior art keywords
derivatives
ghreline
espirocyclic
agronists
piperidine
Prior art date
Application number
CU2013000159A
Other languages
English (en)
Inventor
Ameet Vijay Ambarkhane
Gurdip Shalay
Martin Beckett
James Dale
Ahmed Hamadi
Alessandro Mazzacani
Jefrey Mckenna
Christopher Thomson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48626496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20130159(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2012/052649 external-priority patent/WO2012164473A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20130159A7 publication Critical patent/CU20130159A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a derivados de la fórmula (I), donde los sustituyentes son como se define en la especificación; a procedimientos para la preparación de tales derivados, composiciones farmacéuticas que comprenden tales derivados, tales derivados como un medicamento, tales derivados para el tratamiento de un trastorno o una enfermedad mediada por el receptor de la ghrelina.
CU2013000159A 2012-05-03 2013-11-27 Derivados de la piperidina 3- espirocíclica como agonistas de receptores de la ghrelina CU20130159A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642116P 2012-05-03 2012-05-03
PCT/IB2012/052649 WO2012164473A1 (en) 2011-05-27 2012-05-25 3-spirocyclic piperidine derivatives as ghrelin receptor agonists

Publications (1)

Publication Number Publication Date
CU20130159A7 true CU20130159A7 (es) 2014-02-28

Family

ID=48626496

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2013000159A CU20130159A7 (es) 2012-05-03 2013-11-27 Derivados de la piperidina 3- espirocíclica como agonistas de receptores de la ghrelina

Country Status (20)

Country Link
US (1) US20130296358A1 (es)
EP (1) EP2852591A1 (es)
JP (1) JP2015525202A (es)
KR (1) KR20150003771A (es)
CN (1) CN104271579A (es)
AR (1) AR093748A1 (es)
AU (1) AU2013255458A1 (es)
BR (1) BR112014026210A2 (es)
CA (1) CA2867043A1 (es)
CO (1) CO7111286A2 (es)
CU (1) CU20130159A7 (es)
EA (1) EA201491990A1 (es)
IL (1) IL235215A0 (es)
MA (1) MA20150428A1 (es)
PE (1) PE20142443A1 (es)
PH (1) PH12014502446A1 (es)
SG (1) SG11201405810UA (es)
TN (2) TN2013000441A1 (es)
TW (1) TW201348235A (es)
WO (1) WO2013164790A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536070A (ja) * 2017-09-28 2020-12-10 バイオジェン インコーポレイテッド 新規な塩
KR20240042400A (ko) 2021-07-30 2024-04-02 라퀄리아 파마 인코포레이티드 결정질 형태

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828754B1 (en) 1995-05-29 2005-02-02 Pfizer Inc. Dipeptides which promote release of growth hormone
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
WO1997011697A1 (en) 1995-09-26 1997-04-03 Merck & Co., Inc. 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
AU3220097A (en) 1996-05-22 1997-12-09 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
JP3514774B2 (ja) 1997-06-25 2004-03-31 ファイザー・インク 成長ホルモン分泌促進薬としてのジペプチド誘導体
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
GB9802251D0 (en) 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
NZ510743A (en) 1998-10-02 2003-10-31 Novartis Ag mGluR5 antagonists for the treatment of pain and anxiety
US6194578B1 (en) 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
EP1486498A1 (en) 1998-11-23 2004-12-15 Pfizer Products Inc. Process and intermediates for growth hormone secretagogues
GB9913079D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
DOP2001000154A (es) 2000-05-25 2002-05-15 Pfizer Prod Inc Combinación de secretagogos de hormona del crecimiento y antidepresivos
IL143690A0 (en) 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
GB0028702D0 (en) 2000-11-24 2001-01-10 Novartis Ag Organic compounds
EP1377576A2 (en) 2001-03-26 2004-01-07 Novartis AG Pyridine derivatives
US7109203B2 (en) 2001-05-14 2006-09-19 Novartis Ag Sulfonamide derivatives
JP3894035B2 (ja) 2001-07-04 2007-03-14 東レ株式会社 炭素繊維強化基材、それからなるプリフォームおよび複合材料
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
AU2003218273A1 (en) 2002-04-10 2003-10-27 Eli Lilly And Company Stereoselective process for the synthesis of (d)-2-amino-5-phenylpentanoic or alkyl ester thereof
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
SE0201940D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
AR042206A1 (es) 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
GB0302876D0 (en) 2003-02-07 2003-03-12 Novartis Ag Organic compounds
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2004277318A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
JP2004277319A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物
EP1505064A1 (en) 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
JP2007501821A (ja) 2003-08-12 2007-02-01 エフ．ホフマン−ラ　ロシュ　アーゲー Ｃｆｒアンタゴニストとしてのテトラヒドロキナゾリン誘導体
WO2005013997A1 (en) 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists
EP1664010A1 (en) 2003-08-29 2006-06-07 Vernalis (R&D) Limited Sulfonamides antagonising n-type calcium channels
CA2537127C (en) 2003-09-03 2011-04-05 Pfizer Inc. Benzimidazolone compounds having 5-ht4 receptor agonistic activity
WO2005028480A2 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
BRPI0414087A (pt) 2003-09-05 2006-10-31 Neurogen Corp composto, métodos para tratar um distúrbio, para demostrar a presença de receptores de crf em amostras de célula ou tecido, e para inibir a ligação de crf a um receptor de crf1, composição farmacêutica, e, embalagem
JP2005082508A (ja) 2003-09-05 2005-03-31 Dainippon Pharmaceut Co Ltd ２−アルコキシ−６−アミノ−５−ハロゲノ−ｎ−（１−置換−４−ピペリジニル）ピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
MXPA06002618A (es) 2003-09-09 2006-06-05 Ono Pharmaceutical Co Antagonistas del factor de liberacion de corticotropina (crf) y compuestos heterobiciclicos.
GB0322612D0 (en) 2003-09-26 2003-10-29 Novartis Ag Organic compounds
KR20060111466A (ko) 2003-09-30 2006-10-27 얀센 파마슈티카 엔.브이. 퀴녹살린 화합물
NZ546259A (en) 2003-09-30 2009-05-31 Janssen Pharmaceutica Nv Benzoimidazole compounds
JP2005104896A (ja) 2003-09-30 2005-04-21 Dainippon Pharmaceut Co Ltd ２−アルコキシ−６−アミノ−５−ハロゲノピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
CA2543707A1 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
AU2004289694B2 (en) 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers
US7208596B2 (en) 2003-11-25 2007-04-24 Bristol-Myers Squibb Pharma Company Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
WO2005054239A1 (en) 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
US7211568B2 (en) 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
JP2005206590A (ja) 2003-12-25 2005-08-04 Mitsubishi Pharma Corp ナトリウムチャネルサイト２選択的阻害剤
PT1704146E (pt) 2004-01-07 2010-06-30 Aryx Therapeutics Inc Compostos estereoisoméricos e processos para o tratamento de distúrbios gastrointestinais e do sistema nervoso central
CA2555258C (en) 2004-01-29 2009-04-28 Pfizer Inc. 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4 receptor agonistic activity
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
EP1574478A1 (de) 2004-03-08 2005-09-14 Solvay Fluor GmbH Herstellung von Carbonylfluorid
MXPA06011021A (es) 2004-03-25 2007-04-13 Johnson & Johnson Compuestos de imidazol.
JP2007530694A (ja) 2004-03-29 2007-11-01 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャネル遮断薬としてのビアリール置換ピラジノン
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US20080015196A1 (en) 2004-04-16 2008-01-17 Neurogen Corporation Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands
GB0412768D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
AU2005254800B2 (en) 2004-06-15 2010-12-09 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
WO2006023757A2 (en) 2004-08-19 2006-03-02 University Of Virginia Patent Foundation Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents
GB0420424D0 (en) 2004-09-14 2004-10-20 Ionix Pharmaceuticals Ltd Therapeutic compounds
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
JP5042028B2 (ja) 2004-11-05 2012-10-03 セラヴァンス， インコーポレーテッド キノリノン−カルボキサミド化合物
DE602005016446D1 (de) 2004-11-05 2009-10-15 Theravance Inc 5-HT4-Rezeptoragonistenverbindungen
JP2008519794A (ja) 2004-11-11 2008-06-12 アージェンタ・ディスカバリー・リミテッド ピリミジン化合物
US20060111416A1 (en) 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
KR20070091665A (ko) 2004-12-22 2007-09-11 세라밴스 인코포레이티드 인다졸－카르복사미드 화합물
EP1818061A1 (en) 2005-12-02 2007-08-15 Charite-Universitätsmedizin Berlin Use of ghrelin for stimulating hair growth
CA2677399C (en) 2007-02-09 2016-09-13 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
US7994203B2 (en) 2008-08-06 2011-08-09 Novartis Ag Organic compounds
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
AR086554A1 (es) * 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina

Also Published As

Publication number Publication date
AU2013255458A1 (en) 2014-10-09
AR093748A1 (es) 2015-06-24
BR112014026210A2 (pt) 2017-06-27
EA201491990A1 (ru) 2015-02-27
CO7111286A2 (es) 2014-11-10
KR20150003771A (ko) 2015-01-09
JP2015525202A (ja) 2015-09-03
EP2852591A1 (en) 2015-04-01
TN2014000400A1 (en) 2015-12-21
CA2867043A1 (en) 2013-11-07
PE20142443A1 (es) 2015-01-28
MA20150428A1 (fr) 2015-11-30
SG11201405810UA (en) 2014-11-27
WO2013164790A1 (en) 2013-11-07
TW201348235A (zh) 2013-12-01
US20130296358A1 (en) 2013-11-07
IL235215A0 (en) 2014-12-31
TN2013000441A1 (en) 2015-03-30
CN104271579A (zh) 2015-01-07
PH12014502446A1 (en) 2015-01-12

Similar Documents

Publication Publication Date Title
EA201391797A1 (ru) 3-спироциклические пиперидиновые производные в качестве агонистов грелиновых рецепторов
CU20130036A7 (es) Triazina-oxidazoles
CU20150056A7 (es) Derivados e 1h- bencimidazol como antagonistas de ep4 y medicamentos que los contienen
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
MX2018002326A (es) Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5.
MX2020004855A (es) Metodos utiles en la sintesis de analogos de halicondrina b.
UY33883A (es) Novedosos derivados heterocíclicos
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
BR112016000909A8 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
PE20151067A1 (es) Inhibidores de autotaxina
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
CR20150370A (es) Compuestos antivirales
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
CO6741217A2 (es) Modulares de receptor de glucagón
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
NI201300070A (es) Ureas asimétricas y usos médicos de las mismas
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
ECSP13013016A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como inhibidores de la cinasa del receptor vegf
PE20151003A1 (es) Moduladores alostericos positivos del receptor de acetilcolina nicotinico
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
EA201600166A1 (ru) Производные пиперидина и азепина как модуляторы рецептора прокинетицина
TN2013000441A1 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists